OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

Opko Health Inc/  US68375N1037  /

NASDAQ
5/23/2024  10:00:00 PM Chg. -0.0400 Volume Bid2:33:34 PM Ask2:33:34 PM High Low
1.2800USD -3.03% 2.79 mill.
Turnover: 3.35 mill.		 1.2800Bid Size: 900 1.3100Ask Size: 8,800 1.3300 1.2600
GlobeNewswire 5/15 Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire 5/13 Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Tr...
GlobeNewswire 5/10 Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
GlobeNewswire 5/7 OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
GlobeNewswire 5/3 OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
GlobeNewswire 4/8 Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the...
GlobeNewswire 3/26 Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FD...
GlobeNewswire 3/20 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire 3/8 Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
GlobeNewswire 3/5 AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the ...
GlobeNewswire 3/4 Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire 2/28 AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors
GlobeNewswire 2/27 OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
GlobeNewswire 2/22 OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
GlobeNewswire 2/2 SAB Biotherapeutics Announces Executive Leadership Change
GlobeNewswire 1/30 Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GlobeNewswire 1/9 OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 ...
GlobeNewswire 1/8 OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 1/5 OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029
GlobeNewswire 1/3 OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029
GlobeNewswire 1/3 Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
GlobeNewswire 12/26/2023 Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
GlobeNewswire 11/29/2023 Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatme...
GlobeNewswire 11/14/2023 Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision a...
GlobeNewswire 11/9/2023 Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-...